Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

Michael Vincent, Chief Inflammation & Immunology Officer, Pfizer

“Tilrekimig is a promising investigational medicine in Pfizer’s inflammation and immunology pipeline as we seek to pursue next-generation biologics that address persistent unmet medical needs. The compelling efficacy and tolerability demonstrated in this Phase 2 study validate this multi-pathway, trispecific approach and suggest that tilrekimig has the potential to raise the bar beyond current standard-of-care biologics. Building on these promising findings, we have initiated Phase 3 trials of tilrekimig in atopic dermatitis and asthma, and we are advancing a Phase 2b/3 study in COPD.”

Eric Simpson, Department of Dermatology, Oregon Health & Science University

“Systemic treatment in moderate-to-severe atopic dermatitis has moved from broad immunosuppression to targeted therapy, and that shift has meaningfully changed what we can offer patients. But atopic dermatitis is driven by several inflammatory signals, and a substantial proportion of patients still live with persistent itch and extensive skin involvement. The Week 16 results presented today are meaningful at this stage of development, with tilrekimig’s tolerability profile supporting continued study in a larger patient population.”